Mechanistic description
Astrocytes play a critical role in synaptic pruning and maintenance of neural circuits through complement-mediated elimination of weak or aberrant synaptic connections. This hypothesis proposes that targeted activation of astrocytic complement cascade, specifically through C1q upregulation and subsequent C3 tagging of synapses, can restore optimal functional connectivity patterns in disrupted neural networks. Unlike structural remyelination approaches, this mechanism focuses on refining existing synaptic architecture by selectively eliminating maladaptive connections while preserving or strengthening functionally relevant pathways. Astrocytes would identify synapses for elimination through activity-dependent monitoring of synaptic strength and frequency, using their extensive processes that contact multiple synapses simultaneously. The intervention would involve pharmacological or optogenetic activation of astrocytic complement pathways, particularly targeting the C1q-C3-microglia axis, to enhance pruning efficiency in regions showing aberrant hyperconnectivity or maintaining weak connections that impair network function. This approach shifts from structural white matter repair to functional gray matter optimization, potentially addressing connectome disorders characterized by excessive or inappropriate synaptic connections rather than demyelination. The functional connectome improvements would be measurable through resting-state fMRI, showing increased network efficiency, reduced small-world coefficient disruption, and enhanced modular organization. Evidence would focus on synaptic density changes, complement protein expression levels, microglial activation states, and electrophysiological measures of synaptic strength and network oscillations.
Evidence for (5)
Myelin breakdown is an early, underrecognized feature of AD pathophysiology
Hub regions connected by long-range white matter tracts that are particularly vulnerable
Clemastine promotes OPC differentiation and remyelination in cuprizone and EAE models
Siponimod (Mayzent) FDA-approved for secondary progressive MS
Network-level changes include reduced white matter integrity measurable by diffusion MRI
Evidence against (5)
Myelin changes in AD may be secondary to axonal degeneration - primary vs secondary unresolved
White matter hyperintensities correlate with vascular pathology, not primary OPC dysfunction
Clemastine not advanced to AD clinical trials - off-target antihistamine effects
Siponimod failed in secondary progressive MS - S1P modulation insufficient for established myelin pathology
Aged human OPCs have substantially reduced differentiation capacity vs young animals
Bayesian persona consensus
scidex.consensus.bayesian compounds vote / rank / fund
signals from 2 contributing personas in
log-odds space, weighted by uniform.
Prior 50%.